Case-Based Learning: Solving a Persistent Abdominal-Symptom Case With Changing Gastrointestinal Patterns

Abstract

Persistent abdominal symptoms with evolving gastrointestinal patterns present a diagnostic and management challenge to clinicians. This review employs a case-based learning approach to dissect the complexities of such cases, integrating current epidemiological data, pathophysiological mechanisms, clinical features, diagnostic strategies, treatment modalities, and recent advances. Guideline-driven recommendations are synthesized alongside evidence-based insights to inform the practical approach for healthcare professionals managing patients with fluctuating abdominal presentations.

Introduction

Abdominal complaints are a frequent reason for consultation in both primary care and specialist gastroenterological settings. When symptoms persist and gastrointestinal patterns change over time, the differential diagnosis broadens, requiring systematic evaluation. The clinical significance of such presentations lies in their potential to mask underlying organic pathology, overlap with functional disorders, or represent evolving disease states. This article, structured around a typical case scenario, explores the diagnostic journey and evidence-based management of a patient with persistent, shifting abdominal symptoms, providing clinicians with a framework for targeted investigation and intervention.

Epidemiology / Disease Burden

Chronic abdominal symptoms, including pain, bloating, and altered bowel habits, affect up to 20% of the adult population globally, with significant variation based on age, sex, and geographic region. Functional gastrointestinal disorders (FGIDs) like irritable bowel syndrome (IBS) and organic diseases such as inflammatory bowel disease (IBD) or malignancy may present similarly but differ in epidemiological patterns. IBS, for instance, has a prevalence of 5-15% and is more common in females, whereas IBD is typically diagnosed in younger adults but carries lifelong morbidity. The burden extends beyond physical symptoms, contributing to decreased quality of life, increased healthcare utilization, and substantial economic costs.

Pathophysiology

The pathophysiology underpinning persistent abdominal symptoms with changing patterns is multifactorial. In FGIDs, altered gut-brain axis signaling, visceral hypersensitivity, dysbiosis, and low-grade mucosal inflammation are implicated. Organic etiologies such as IBD or colorectal cancer involve immune dysregulation, genetic predisposition, and environmental triggers leading to mucosal injury and remodeling. Evolving patterns may reflect disease progression, treatment response, or superimposed complications such as bacterial overgrowth, strictures, or neoplasia. Mechanistic understanding informs the rationale for a stepwise and individualized clinical approach.

Risk Factors

Risk factors for persistent and evolving abdominal symptoms are both host- and environment-related. These include female sex, psychological stress, family history of GI diseases, prior GI infections, dietary factors, and antibiotic exposure. Inflammatory and neoplastic conditions are linked to genetic susceptibility, autoimmune tendencies, and chronic inflammatory states. Recognition of these risk factors aids in risk stratification and targeted diagnostic work-up, especially in patients with alarm features (e.g., weight loss, rectal bleeding, anemia).

Clinical Features

Patients may present with a constellation of symptoms such as intermittent or constant abdominal pain, bloating, altered bowel habits (constipation, diarrhea, or alternating), nausea, and systemic signs (fatigue, fever, weight loss). The temporal evolution waxing and waning, stepwise progression, or abrupt changes provides diagnostic clues. Physical findings can be nonspecific but may include abdominal tenderness, palpable masses, or signs of peritonism in acute presentations. The presence of alarm symptoms necessitates expedited investigation to exclude serious underlying pathology.

Diagnosis

Diagnosis requires a structured, algorithmic approach integrating clinical history, physical examination, and judicious use of investigations. Initial laboratory tests include complete blood count, inflammatory markers (CRP, ESR), liver and renal panels, and celiac serology. Stool studies (calprotectin, occult blood, pathogens) help differentiate inflammatory from functional etiologies. Imaging modalities such as abdominal ultrasound, CT, or MRI are employed to assess structural abnormalities, while endoscopic evaluation (colonoscopy, upper GI endoscopy) is indicated in cases with alarm features or persistent unexplained symptoms. Rome IV criteria guide the diagnosis of FGIDs, while histopathology confirms organic disease. Multidisciplinary collaboration with radiologists and pathologists enhances diagnostic accuracy.

Treatment & Management

Management is etiology-specific, with a strong emphasis on symptom control and addressing underlying pathology. For FGIDs, a combination of dietary modification (low FODMAP), pharmacotherapy (antispasmodics, laxatives, antidiarrheals, neuromodulators), and behavioral therapies (CBT) is recommended. In IBD, aminosalicylates, corticosteroids, immunomodulators, and biologics are tailored to disease severity and phenotype. Malignancy requires oncological referral for staging and intervention. Regular follow-up and reassessment are crucial, given the potential for symptom evolution and emergence of new findings. Patient-centered communication and education underpin successful long-term outcomes.

Recent Advances / Emerging Therapies

Recent years have seen advances in diagnostic biomarkers (fecal calprotectin, serum microRNAs), non-invasive imaging, and molecular profiling, which facilitate earlier and more precise differentiation between functional and organic disorders. Emerging therapies for FGIDs include novel gut-directed antibiotics (rifaximin), prokinetics, and microbiota-based interventions (fecal microbiota transplantation). In IBD, the therapeutic landscape has expanded to include JAK inhibitors, sphingosine-1-phosphate modulators, and personalized medicine approaches based on genetic and immunological profiling. Integration of artificial intelligence in endoscopic and radiological assessment shows promise for enhanced diagnostic yield.

Guideline Recommendations

Consensus guidelines from gastroenterological societies emphasize a stepwise diagnostic approach, with prompt investigation for alarm features and judicious use of invasive procedures. For FGIDs, Rome IV criteria and symptom-based management are endorsed, while IBD management follows a treat-to-target paradigm with regular assessment of disease activity. Multidisciplinary care, patient education, and individualized treatment plans are universally recommended, alongside ongoing monitoring for disease progression or complication development.

Conclusion

Persistent abdominal symptoms with fluctuating gastrointestinal patterns demand a high index of suspicion, systematic evaluation, and evidence-based management. Clinicians should integrate epidemiological context, mechanistic insights, and current guidelines to optimize outcomes. Ongoing research and emerging therapies offer hope for improved diagnosis and treatment, underscoring the importance of continuous learning and multidisciplinary collaboration in contemporary gastroenterological practice.